Resistin and inflammation in pulmonary hypertension
Official title: Resistin regulates NLRP3 inflammasome in pulmonary hypertension
Funded at Johns Hopkins University · NIH-11393039 · Data updated 2026-11-12
This NIH grant explores how resistin and related molecules drive inflammation in people with pulmonary hypertension and how this could lead to new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $688,819 |
| NIH project number | 5R01HL166717-04 |
| Project ID | NIH-11393039 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with pulmonary hypertension or related inflammatory vascular conditions may be eligible for future trials or related studies.
✕Less likely to help
People without pulmonary hypertension or those not involved in inflammation-related projects may not directly benefit.
What this research studies
If you have pulmonary hypertension or related inflammatory conditions, this grant studies how resistin signals in your lungs and immune cells to promote disease progression. Researchers will look at how resistin interacts with inflammatory pathways like HMGB1 and the NLRP3 inflammasome, and how Bruton’s Tyrosine Kinase (BTK) might link these processes. The project aims to map the sequence of immune events from early injury to vascular remodeling, with the goal of identifying targets for therapy. The work is conducted at Johns Hopkins University under a translational research framework to connect basic science findings with potential patient benefits.
Why it matters
Potential benefit: A better understanding of inflammatory pathways could lead to new treatments that slow or reverse pulmonary hypertension.
How similar studies have gone: Prior work shows resistin-related inflammation is linked to PH, supporting a plausible impact if targets are validated.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Johns, Roger a — Johns Hopkins University
- Study coordinator: Johns, Roger a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
-
CD4 T Cells, Schistosoma, and Pulmonary Hypertension: Understanding How Immune Cells Drive Disease
A human-health focused study uses a mouse model and human samples to explore how immune cells and inflammation may contribute to a lung blood vessel disease linked to schistosomiasis.
-
CD4 T Cells and Schistosoma-Related Pulmonary Hypertension
A study to understand how specific immune cells behave in a lung complication caused by schistosomiasis, with the goal of finding targets to prevent or treat it.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Right heart remodeling in pulmonary hypertension
In people with pulmonary hypertension, researchers are studying how the right side of the heart changes and why it fails, with the goal of finding new treatments.
-
TEMPO-PH: How the right heart adapts in pulmonary hypertension over time
A study to build a detailed molecular portrait of why the right side of the heart fails in pulmonary hypertension and how a common heart medicine might help.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.